Provided for non-commercial research and education use. Not for reproduction, distribution or commercial use.



This article appeared in a journal published by Elsevier. The attached copy is furnished to the author for internal non-commercial research and education use, including for instruction at the authors institution and sharing with colleagues.

Other uses, including reproduction and distribution, or selling or licensing copies, or posting to personal, institutional or third party websites are prohibited.

In most cases authors are permitted to post their version of the article (e.g. in Word or Tex form) to their personal website or institutional repository. Authors requiring further information regarding Elsevier's archiving and manuscript policies are encouraged to visit:

http://www.elsevier.com/copyright

Molecular and Cellular Endocrinology 347 (2011) 11-16

ELSEVIER

Contents lists available at ScienceDirect

### Molecular and Cellular Endocrinology

journal homepage: www.elsevier.com/locate/mce

# Review VDR activation of intracellular signaling pathways in skeletal muscle

### Ricardo L. Boland\*

Departamento de Biología, Bioquímica y Farmacia, Universidad Nacional del Sur, San Juan 670, 8000 Bahia Blanca, Argentina

### ARTICLE INFO

Article history: Received 9 March 2011 Received in revised form 8 May 2011 Accepted 8 May 2011 Available online 1 June 2011

Keywords: VDR Muscle Cell signaling 1α,25(OH)<sub>2</sub>D<sub>3</sub> Non-genomic effects

Contents

#### ABSTRACT

The purpose of this article is to review the activation of signal transduction pathways in skeletal muscle cells by the hormone  $1\alpha$ ,25(OH)<sub>2</sub>-vitamin D<sub>3</sub> [ $1\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub>], focusing on the role of the vitamin D receptor (VDR). The hormone induces fast, non transcriptional responses, involving stimulation of the transmembrane second messenger systems adenylyl cyclase/cAMP/PKA, PLC/DAG + IP<sub>3</sub>/PKC, Ca<sup>2+</sup> messenger system and MAPK cascades. Short treatment with  $1\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub> induces reverse translocation of the VDR from the nucleus to plasma membranes. Accordingly, a complex is formed in the caveolae between the VDR and TRCP3, integral protein of capacitative Ca<sup>2+</sup> entry (CCE), suggesting an association between both proteins and a functional role of the VDR in  $1\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub> activation of CCE. Stimulation of tyrosine phosphorylation cascades by  $1\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub> have demonstrated the formation of complexes between Src and the VDR. Through these mechanisms,  $1\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub> plays an important function in contractility and myogenesis.

© 2011 Elsevier Ireland Ltd. All rights reserved.

1.	Introduction	11
2.	Non-genomic regulation of skeletal muscle intracellular signaling pathways by 1α,25(OH) <sub>2</sub> D <sub>3</sub>	
	2.1. Regulation of intracellular Ca <sup>2+</sup> messenger system	12
	2.2. Regulation of PLC/PLD/PLA <sub>2</sub> /PKC pathways	12
	2.3. Regulation of the adenylyl cyclase/cAMP/PKA pathway	13
	2.4. Regulation of tyrosine phosphorylation cascades	13
3.	Subcellular localization and translocation of the VDR in skeletal muscle cells	13
4.	Role of the VDR in the activation of skeletal muscle cell signaling by $1\alpha$ , $25(OH)_2D_3$	14
	Novel putative $1\alpha_2 25(OH)_2 D_3$ receptors mediating non-genomic actions	14
	Acknowledgements	15
	References	15

#### 1. Introduction

 $1\alpha$ ,25-dihydroxy-vitamin D<sub>3</sub> ( $1\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub>) acts, as other steroid hormones, through two different mechanisms. In addition to regulating expression of target genes via its specific nuclear receptor (VDR), the hormone induces fast, non transcriptional responses involving stimulation of transmembrane second messenger systems, e.g. adenylyl cyclase/cAMP/PKA, PLC/DAG + IP<sub>3</sub>/PKC, intracellular Ca<sup>2+</sup> and MAPK cascades. The rapid nature and specificity by which  $1\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub> triggers the activation of these second messengers has led to the concept that interaction with a

\* Tel.: +54 291 4595101x2430; fax: +54 291 4595130. *E-mail address:* rboland@criba.edu.ar plasma membrane receptor is responsible for the initiation of its effects. However, there is controversy over its molecular characteristics. Among several proposals for non-genomic receptor identity, it has been suggested the existence of membrane associated forms of either the classical receptor (VDR) or alternatively novel hormone binding proteins. This chapter focuses on  $1\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub> regulation of intracelullar signaling pathways and its relationship to the presence of the VDR in the plasma membrane of myoblasts/myotubes, a cell system model for skeletal muscle in which  $1\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub> signal transduction mechanisms have been intensively studied.  $1\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub> is essential for normal homeostasis of intracellular calcium and growth in skeletal muscle, and thereby plays an important role in contractility and myogenesis. Consequently, a myopathy characterized by muscle



<sup>0303-7207/\$ -</sup> see front matter @ 2011 Elsevier Ireland Ltd. All rights reserved. doi:10.1016/j.mce.2011.05.021

weakness and atrophy is observed in vitamin D-deficiently states (Boland, 1986).

## 2. Non-genomic regulation of skeletal muscle intracellular signaling pathways by $1\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub>

#### 2.1. Regulation of intracellular Ca<sup>2+</sup> messenger system

The non-genomic regulation of intracellular Ca<sup>2+</sup> in myoblasts/ myotubes by  $1\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub> has been well characterized. Various aspects of this mechanism have been reproduced using differentiated soleus skeletal muscle in vitro, whereby the hormone elicits rapid effects (1–15 min) on <sup>45</sup>Ca<sup>2+</sup> uptake, which are not blocked by inhibitors of RNA and protein synthesis but are suppressed by blockers of voltage-dependent calcium channels (VDCC) (de Boland and Boland, 1987). Interestingly, a rapid stimulation of skeletal muscle calcium fluxes in response to  $1\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub> has also been observed in vivo (Bauman et al., 1984). In myoblasts the operation of this mechanism has been firmly established by the fact that  $1\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub>-dependent Ca<sup>2+</sup> influx could be mimicked by the VDCC agonist BAY K8644, and plasma membrane depolarization induced by a high K<sup>+</sup> medium. The effects of the combined treatment with  $1\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub> and BAY K8644 or K<sup>+</sup> depolarization were not additive. Moreover, the action of the hormone was dependent on extracellular Ca<sup>2+</sup> as they were reversible inhibited by the Ca<sup>2+</sup> chelator EGTA. Furthermore, on the basis of their sensitivity to nifedipine and verapamil, the voltage-dependent Ca<sup>2+</sup> channels activated in skeletal muscle cells by  $1\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub> were pharmacologically identified as from the L-type (Vazquez and de Boland, 1993; de Boland and Boland, 1994).

 $1\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub> rapidly regulates muscle cell Ca<sup>2+</sup> influx by guanine nucleotide binding (G) protein mediated activation of both phospholipase C and adenylyl cyclase, leading to the stimulation or PKC and PKA and subsequent activation of VDCC by phosphorylation (Sections 2.2 and 2.3, respectively).

Spectrofluorometric studies with Fura-2-loaded muscle cells have confirmed the above observations and revealed additional key information related to the regulation of muscle intracellular  $Ca^{2+}$  homeostasis by  $1\alpha, 25(OH)_2D_3$ . The cytosolic  $Ca^{2+}$  response to the hormone involves an initial rapid sterol-induced Ca<sup>2+</sup> mobilization from IP<sub>3</sub>/thapsigargin-sensitive stores followed by cation influx from the extracellular milieu, accounting for a sustained  $Ca^{2+}$  phase which does not return to baseline as long as the cells are exposed to the sterol. This Ca<sup>2+</sup> influx was shown to be contributed not only by the well established L-type VDCC mediated  $Ca^{2+}$ entry but also by a store-operated Ca<sup>2+</sup> (SOC; capacitative Ca<sup>2+</sup> entry, CCE) channel, therefore introducing a novel aspect into the mechanism of  $1\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub>-induced Ca<sup>2+</sup> influx across the plasma membrane of muscle cells (Vazquez et al., 1997a,b, 1998). The SOC influx activated by  $1\alpha$ ,  $25(OH)_2D_3$  was identified by being insensitive to L-type Ca<sup>2+</sup> channel antagonists but was fully inhibitable by low micromolar concentrations of  $La^{3+}$  (3  $\mu$ M) and Ni<sup>2+</sup>. PI(polyphosphoinositide)-specific PLC blockade prior to  $1\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub> stimulation suppressed both the cytosolic Ca<sup>2+</sup> transient and SOC influx. Accordingly, depletion of intracellular Ca<sup>2+</sup> stores by thapsigargin reproduced  $1\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub>-induced Ca<sup>2+</sup> influx, inhibiting any further response to the hormone. Furthermore, 1α,25(OH)<sub>2</sub>D<sub>3</sub> increased the rate of quenching of Fura-2 fluorescence by Mn<sup>2+</sup>, indicating activation of Mn<sup>2+</sup> influx which specifically permeates SOC channels (Vazquez et al., 1997a,b, 1998).

There is evidence on the involvement of protein kinases in the regulation of capacitative calcium influx in muscle cells by  $1\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub>. It has been shown that the hormone stimulated CCE is prevented by inhibitors of PKC (calphostin C, bisindolyl-maleimide) and tyrosine kinase (genistein) but unaffected by

blockade of the PKA pathway (Vazquez et al., 1998). Of relevance, SOC influx stimulated by  $1\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub> is insensitive to both calmodulin (CAM) antagonists and CAM-dependent protein kinase II (CAMKII) inhibitors when added after the IP<sub>3</sub>-mediated Ca<sup>2+</sup> transient but completely abolished when added before it. Moreover, in cells microinjected with antisense oligonucleotides directed against the CAM mRNA the sterol stimulated SOC influx is reduced up to 60% respect to uninjected cells (Vazquez et al., 2000). These results suggest that the  $1\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub>-induced (IP<sub>3</sub>-mediated) cytosolic Ca<sup>2+</sup> transient is required for CAM activation which in turn mediates SOC influx in a mechanism that seems to include CAMKII.

#### 2.2. Regulation of PLC/PLD/PLA<sub>2</sub>/PKC pathways

There is a wealth of information showing that  $1\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub> also exerts nongenomic actions at the level of transmembrane second messenger systems, which mediate the fast effects of the hormone on muscle intracellular Ca<sup>2+</sup> regulation. It has been shown that 1 $\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub> modifies the activity of myoblast phospholipases in a mode independent of the nucleus. Within seconds to minutes the hormone activates phospholipase C (PLC) generating the second messengers inositol trisphosphate (IP<sub>3</sub>, a Ca<sup>2+</sup> mobilizer) and diacylglycerol (DAG, a PKC activator) from membrane phosphoinositides (Morelli et al., 1993). The formation of DAG is biphasic, with the second phase independent of IP<sub>3</sub> release. 1α,25(OH)<sub>2</sub>D<sub>3</sub> also stimulates the rapid hydrolysis of phosphatidylcholine (PC) in myoblasts by a phospholipase D (PLD)-catalyzed mechanism. PLD activity generates choline and phosphatidic acid which in turn can be converted to diacylglycerol by the action of a phosphohydrolase, accounting for the second peak of DAG observed in response to the hormone (de Boland et al., 1994). In addition,  $1\alpha$ ,  $25(OH)_2D_3$  activates phospholipase A<sub>2</sub> (PLA<sub>2</sub>) and the subsequent release of arachidonic acid. Rapid modulation of myoblast PLC, PLD and is PLA2 is 1a,25(OH)<sub>2</sub>D<sub>3</sub> specific, as 25(OH)D<sub>3</sub> and  $24,25(OH)_2D_3$  do not influence enzyme activities.

The rapid activation of phospholipases by  $1\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub> involves the participation of G proteins. (AlF4)- and the stable analogue GTP $\gamma$ S, which activate G proteins, mimic hormone stimulation of PLA2-mediated arachidonic acid (AA) release from myoblasts prelabeled with [<sup>3</sup>H]AA, whereas GDP $\gamma$ S and Bordetella pertussis toxin pretreatment abolish  $1\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub>-dependent AA release (de Boland et al., 1995). By using similar experimental approaches, it has been shown that like PLA2, hormone modulation of PLC and PLD, is mediated by a pertussis toxin-sensitive GTP-binding protein (Morelli et al., 1996).

In agreement with the  $1\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub>-induced generation of DAG via PLC and PLD, it has been reported that the hormone rapidly translocates protein kinase C into the cell membrane and increases its activity in chick muscle soleus muscle in vitro as well as in cultured embryonic muscle cells. In addition, the participation of protein kinase C in the fast  $1\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub> stimulation of <sup>45</sup>Ca<sup>2+</sup> influx through VDCC channels is supported by experimental evidence obtained with phorbol esters and DAG analogues, which mimic the action of the hormone, as well as PKC inhibitors, which reduce its effects (Massheimer and de Boland, 1992; Vazquez and de Boland, 1996). Recent studies have revealed that PKC $\alpha$  is the only PKC isoform activated and translocated from cytosol to the membrane upon  $1\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub> stimulation of muscle cells (Capiati et al., 2000). Moreover, transfection of specific anti-PKC $\alpha$  antibodies or intranuclear microinjection of antisense oligonucleotides against PKCa mRNA coupled to spectrofluorimetric analysis of changes in intracellular Ca<sup>2+</sup> in Fura-2-loaded myoblasts/myotubes shows a marked reduction of hormone-dependent Ca<sup>2+</sup> influx (Capiati et al., 2000, 2001).

#### 2.3. Regulation of the adenylyl cyclase/cAMP/PKA pathway

There are also data implying the participation of the adenylyl cyclase (AC)/cAMP pathway in the non-genomic mode of action of  $1\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub> in muscle. Physiological concentrations of the hormone elicit very fast (within 30 s) increases in AC, cAMP levels and PKA activity in both intact differentiated muscle and cultured myoblasts/myotubes.  $1\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub> stimulation of dihydropyridine-sensitive Ca<sup>2+</sup> influx is abolished by specific inhibitors of AC and PKA and mimicked by forskolin and dibutyryl cAMP, involving the AC/cAMP/PKA pathway in the hormone non-genomic modulation of VDCC (Fernandez et al., 1990; Vazquez et al., 1995).

Studies with muscle cells and tissue on the effects of G protein modulators, e.g. fluoride, GTPγS, GDPγS, cholera and Bordetella pertussis toxins, on  $1\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub>-mediated Ca<sup>2+</sup> uptake, as well as the observation of hormone induced decrease of [<sup>35</sup>S]GTP<sub>y</sub>S binding to membranes and increased ADP ribosylation of the pertussis toxinsensitive 41 kDa substrate, led to propose that negative regulation of an inhibitory protein coupled to AC is part of the mechanism by which  $1\alpha_{2}$  (OH)<sub>2</sub>D<sub>3</sub> increases Ca<sup>2+</sup> influx through the cAMP dependent pathway (Vazquez et al., 1995; Boland et al., 1991). Direct evidence on the involvement of G proteins in the fast activation of adenylyl cyclase by  $1\alpha$ , 25(OH)<sub>2</sub>D<sub>3</sub> has been obtained in experiments in which the effect of the hormone on AC, GTPase and PKA activities as well as on the phosphorylation of  $G\alpha i$  was studied in membranes from chick skeletal muscle cells (Vazquez et al., 1997a,b). 1a,25(OH)<sub>2</sub>D<sub>3</sub> stimulates AC activity provided GTP is present in the assay. High affinity GTPase, related to Gs, is unaffected by the hormone. In the absence of GTP or in the presence of a high concentration of Mn<sup>2+</sup>, a condition which provides information on adenylyl cyclase activity devoid of G-protein regulation, 1α,25(OH)<sub>2</sub>D<sub>3</sub> effects on AC are abolished. PKA activity is increased in cells pretreated with the hormone. Moreover, immunoprecipitation of Gαi from [<sup>32</sup>P]-labeled myoblast membranes shows that  $1\alpha$ ,  $25(OH)_2D_3$  increases the phosphorylation of its  $\alpha$  subunit. Therefore, these data altogether indicate that in muscle cells 1a,25(OH)<sub>2</sub>D<sub>3</sub> activates adenylyl cyclase by a GTP-dependent action implying, as suggested before, amelioration of Gi function by hormone-induced  $\alpha$ i phosphorylation (Vazquez et al., 1997a,b)

#### 2.4. Regulation of tyrosine phosphorylation cascades

Stimulation of tyrosine phosphorylation pathways plays an important role in the mechanism which mediates the effects of  $1\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub> on muscle growth. Tyrosine phosphorylation is a crucial event in signal transduction linked to the mitogen-activated protein kinase (MAPK). Stimulation of the MAP ERK1/2 cascade may occur through activation of receptor tyrosine kinases or G protein-coupled receptors by stimulation of non-receptor Src kinases or by direct signalling to Raf via PKC. Upon phosphorylation by mitogens, ERK1/2 is translocated from the cytoplasm into the nucleus which results in the activation or induction of transcription factors leading to the expression of genes involved in the control of cellular growth (Neary, 1997).

 $1\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub> rapidly promotes in cultured myoblasts tyrosine phosphorylation of ERK1/2, PLC $\gamma$  and the c-myc oncoprotein (Morelli et al., 2000). Fast  $1\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub>-dependent increased Src kinase activity has been observed in myoblasts (Buitrago et al., 2000).

Preincubation of muscle cells with specific Src inhibitors or their transfection with an antisense ODN against Src mRNA inhibits  $1\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub> activation of ERK1/2 involving Src as an upstream element which leads to hormone signaling through this cascade (Buitrago et al., 2001b). Of interest, recent studies applying siRNA technology, confocal immunocytochemistry and co-immunoprecipitation, have shown that  $1\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub> stimulation of Src is mediated by the sequential participation of PKC $\delta$  and protein tyrosine phosphatase (PTP)α, PTPα activating Src by dephosphorylating its Tyr530 (Buitrago and Boland, submitted).

In addition, there is evidence that calcium and protein kinase C are also involved in the stimulation of ERK1/2 by 1a,25(OH)2D3 (Morelli et al., 2001). Recent investigations (Buitrago et al., 2003) have established the role of PKC and besides uncovered other metabolic steps which participate in hormone upregulation of the ERK1/2 cascade. Thus, 1a,25(OH)<sub>2</sub>D<sub>3</sub> causes a fast significant increase of Raf-1-serine phosphorylation, indicating activation of Raf-1 by the hormone. The PKC inhibitors calphostin C, bisindolylmaleimide I and Ro 318220 blocked 1a,25(OH)<sub>2</sub>D<sub>3</sub>-induced Raf-1 serine phosphorylation, revealing that PKC participates in hormone stimulation of ERK1/2 at the level of Raf-1. Moreover, application of antisense oligonucleotide technology revealed that PKC $\alpha$  specifically mediates this action. In addition, by using a specific Ras peptide inhibitor, Ras has also been involved in  $1\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub> activation of Raf-1. The hormone rapidly induced tyrosine dephosphorylation of Ras-GTPase-activating protein, suggesting that inhibition of Ras-GTP hydrolysis is part of the mechanism by which  $1\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub> activates Ras in myoblasts (Buitrago et al., 2003).

Stimulation of tyrosine phosphorylation cascades bv  $1\alpha_2 25(OH)_2 D_3$  through the above described mechanisms causes translocation of ERK1/2 from the cytoplasm to the nucleus in active phosphorylated form and induces the expression of the growthrelated protein c-myc, as the MAPK kinase (MEK) inhibitor PD98059 abolishes stimulation of c-myc synthesis bv  $1\alpha_2 25(OH)_2 D_3$  (Buitrago et al., 2001b). There is also information available on the signaling cascade leading to PLC $\gamma$  activation, a relevant event which may account for the activation of PKC $\alpha$  (followed by that of Raf-1) via release of DAG and IP<sub>3</sub>-mediated Ca<sup>2+</sup>. Investigations based on the utilization of specific inhibitors and antisense technology have involved Src and phosphatidylinositol 3-kinase (PtdIns3K) in  $1\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub> stimulation of PLC $\gamma$  tyrosine phosphorylation and its translocation to the cell membrane. Evidence has been obtained indicating that the hormone increases the physical association of Src and PtdIns3K with PLC $\alpha$  and induces a Src-dependent tyrosine phosphorylation of the p85 regulatory subunit of PtdIns3K (Buitrago et al., 2002).

There is evidence that other members of the MAP kinase superfamily are also activated by the hormone in muscle cells (Buitrago et al., 2006) as shown in different target cells (Boland et al., 2005).  $1\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub> has been shown to rapidly stimulate (within 1 min) MKK3/MKK6/p38 MAPK through Src in C2C12 cells. Of relevance, the hormone induced in the C2C12 line the stimulation of mitogen-activated protein kinase activating protein kinase 2 (MAP-KAP-kinase 2) and subsequent phosphorylation of heat shock protein 27 (HSP27) in a p38 kinase activation-dependent manner.  $1\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub> also promotes the phosphorylation of JNK 1/2 (0.5– 1 min). The relative contribution of ERK-1/2, p38, and JNK-1/2 and their interrelationships in hormonal regulation of muscle cell proliferation and differentiation remain to be established.

Altogether,  $1\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub> stimulates in muscle cells an intricate network of signaling components and interacting pathways, which provide a mechanism underlying regulation of muscle cellular growth by the hormone.

## 3. Subcellular localization and translocation of the VDR in skeletal muscle cells

The presence of the VDR in skeletal muscle has been clearly demonstrated in avian, murine and human cells and tissue by characterization of biochemical properties, detection of VDR-mRNA by RT-PCR and anti-VDR antisense ODNs, Western blot and immunocytochemical analysis using highly specific antibodies (Boland et al., 1985; Simpson et al., 1985; Costa et al., 1986; Zanello et al., 1997; Buitrago et al., 2001a; Capiati et al., 2002; Santillán et al., 2004b), although a recent study demonstrating the expression of small amounts of VDR mRNA in skeletal muscle, has failed to detect the receptor protein by immunohistochemistry and immunoblot assays (Wang and DeLuca, 2011). It is possible that differences in experimental conditions precluded these authors to detect considerable lower levels of VDR in muscle than in the duodenal tissue they used as positive control. Accumulation of the receptor at specific muscle cell sites like the plasma membrane/caveolae (Capiati et al., 2002; Buitrago and Boland, 2010) may be sufficient to sustain  $1\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub> triggered non-genomic signaling.

In accord with the several lines of evidence showing rapid nongenomic effects of  $1\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub> on various signaling systems, it has been observed that short treatment with the hormone induces the translocation of the VDR from the nucleus to the plasma membrane in chick skeletal muscle cells (Capiati et al., 2002). In these studies a high degree of purity of both fractions was evidenced by measurement of specific markers of subcellular components. The  $1\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub>-dependent intracellular redistribution of the VDR was blocked by genistein, herbimycin or colchicine, suggesting the involvement of tyrosine kinase/s and microtubular transport in the relocation of the receptor.

In agreement with the above observations, interactions of the nuclear VDR-1 $\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub> complex with plasma membrane acceptance sites have been reported for osteoblastic ROS 17/2.8 cells (Kim et al., 1996). Plasma membrane components have been involved in the initiation of non-transcriptional rapid responses induced by  $1\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub> through activation of MAPKs in skeletal muscle cells mentioned before. Thus, there is evidence that caveolae and caveolin-1 (cav-1) participate in hormone stimulation of c-Src and MAPKs in C2C12 murine myoblasts (Buitrago and Boland, 2010). When proliferating cells were pretreated with methyl beta cyclodextrin (MβCD), a caveolae disrupting agent, under conditions in which cell morphology is not affected and no signs of apoptosis are observed, 1a,25(OH)<sub>2</sub>D<sub>3</sub>-dependent activation of ERK1/2, p38 MAPK and c-Src was suppressed. Similar results were obtained by siRNA technology whereby silencing of cav-1 expression abolished activation of c-Src and MAPKs induced by the hormone. Confocal immunocytochemistry and co-immunoprecipitation assays showed that cav-1 colocalizes with c-Src in the periplasma membrane zone at basal conditions, whereas  $1\alpha$ ,  $25(OH)_2D_3$  treatment disrupted the colocalization of these proteins and redistributed them into cytoplasm and nucleus. Moreover, confocal microscopy revealed that the hormone induces VDR translocation to the plasma membrane as shown before by cell fractionation studies (Capiati et al., 2002), and this effect is abolished by MBCD. Altogether, these data suggest that caveolae is involved upstream in c-Src-MAPKs activation by  $1\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub> and that VDR and cav-1 participate in the rapid signaling elicited by the hormone (Buitrago and Boland, 2010). In line with these observations, studies in different cell types have also demonstrated the presence of VDR associated with plasma membrane caveolae (Norman et al., 2002; Huhtakangas et al., 2004), although no evidence was presented on a functional role of the membrane VDR in non-genomic modulation of signaling pathways. Interestingly, the identification of an alternative ligand-binding pocket in the nuclear VDR has allowed to generate by computer docking a receptor conformational ensemble model providing an explanation for how VDR can have genomic and non-genomic functions (Mizwicki et al., 2004a,b, 2005).

# 4. Role of the VDR in the activation of skeletal muscle cell signaling by $1\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub>

In agreement with the data described above (Section 3) demonstrating translocation from the nucleus and localization of the classic VDR into the caveolae of skeletal muscle cells induced by  $1\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub>, various lines of evidence indicate that membraneassociated VDR is the receptor that mediates the non-genomic effects of the hormone. Thus, the mechanism of 1a,25(OH)<sub>2</sub>D<sub>3</sub> regulation of store operated Ca<sup>2+</sup> influx in muscle cells supports this concept. The structural components of SOC channels are the TRPC (Transient Receptor Potential-canonical) proteins, which function as Ca<sup>2+</sup> permeable channels regulated by intracellular store depletion. At present, seven mammalian TRPC proteins are at least known (TRPC1-TRPC7), which are homologs of the Drosophila melanogaster counterparts (Birnbaumer et al., 1996). There is molecular and immunochemical evidence which confirms the endogenous expression of a TRPC3-like protein in muscle cells. Transfection of myoblasts with anti-TRPC3 antisense ODNs shows reduced CCE induced by  $1\alpha_2 25(OH)_2 D_3$ . Anti-VDR antisense ODNs also inhibit hormone-dependent SOC Ca<sup>2+</sup> influx and co-immunoprecipitation of TRPC3 and VDR is observed suggesting an association between both proteins and a functional role of the receptor in 1α,25(OH)<sub>2</sub>D<sub>3</sub> activation of CCE (Santillán et al., 2004a,b,c). Accordingly, it has been mentioned before (Section 3) that short treatment with  $1\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub> induces translocation of the VDR from the nucleus to plasma membranes in chick myoblasts/myotubes (Capiati et al., 2002).

TRP channels have been shown to be modulated by association of macromolecules integrating signaling supramolecular complexes. The scaffold protein INAD clusters these macromolecules through its PDZ domains (Huber et al., 1998). A functional role for an INAD-like protein in hormone activation of CCE is inferred by the reduction of  $1\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub>-induced Ca<sup>2+</sup> influx upon transfection of muscle cells with an anti-INAD antibody or microinjection with anti-INAD antisense ODNs (Boland, 2005). In addition to TRPC3 and VDR, other components of the putative signaling complex may be calmodulin/CaMKII and Src, which have been shown to interact with TRP proteins and the VDR (Buitrago et al., 2001a; see below), respectively, in keeping with the fact that CaM antagonists and inhibitors of CaMKII as well as of tyrosine kinases block  $1\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub>-induced SOC influx (Vazquez et al., 1998, 2000).

There is evidence indicating that the VDR is involved in the nongenomic stimulation of tyrosine phosphorylation cascades by  $1\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub> in muscle cells. Coimmunoprecipitation analysis have provided evidence that  $1\alpha$ ,  $25(OH)_2D_3$  promotes the formation of complexes between Src and the VDR, and Src and c-myc (Buitrago et al., 2000), which can be explained by the fact that both the VDR and c-myc behave as 1a,25(OH)<sub>2</sub>D<sub>3</sub>-dependent tyrosine phosphorylated proteins and may interact with Src through the SH2 domain of the latter. Preincubation of myoblasts with a pool of different antisense ODNs against the VDR mRNA (AS-VDR ODNs) significantly reduces Src stimulation, further implying the VDR in hormone activation of Src (Buitrago et al., 2001a). Although not fully, ERK1/2 tyrosine phosphorylation by  $1\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub> is affected by transfection with AS-VDR ODNs implying that VDR-dependent signaling mediates hormone stimulation of the ERK cascade (Buitrago et al., 2001a; Boland et al., 2002).

#### 5. Novel putative $1\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub> receptors mediating nongenomic actions

First studies have suggested the existence of a  $1\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub> binding protein different from the nuclear VDR in the plasma membrane of chick enterocytes which mediates rapid hormone stimulation of intestinal Ca<sup>2+</sup> transport and PKC activity (Nemere et al., 1994, 1998). Alternatively, it has been reported that annexin II may be the membrane receptor that mediates  $1\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub>-induced rapid increases in cytosolic Ca<sup>2+</sup> in rat osteoblast-like cells

R.L. Boland/Molecular and Cellular Endocrinology 347 (2011) 11-16

ROS 24/1 which do not express the VDR (Baran et al., 2000). However, subsequent studies have provided evidence that annexin II does not bind  $1\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub> in a physiologically relevant manner casting doubts on the possibility that it is a putative membrane receptor for the hormone (Mizwicki et al., 2004a,b). It has also been reported that another cell surface receptor for  $1\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub> termed MARRS (Membrane Associated, Rapid Response Steroid binding), identical to the thiol-protein disulphide oxidoreductase Erp57/ GRp58/ERp60 may mediate several  $1\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub>-induced effects in various cell types, including certain cancer cells, chondrocytes and muscle (Boyan et al., 2006; Khanal and Nemere, 2007; Richard et al., 2010). In addition, recent studies have provided evidence on a novel  $1\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub> putative receptor, namely protein-disulfide isomerase-associated 3 (Pdia3), as an initiator of hormone-stimulated membrane signaling pathways (Chen et al., 2010).

#### Acknowledgements

The author is indebted to current and previous laboratory colleagues who have contributed during various phases of the investigations, in particular Ana R. de Boland, Susana Morelli, Guillermo Vazquez, Claudia Buitrago, Graciela Santillàn and Daniela Capiati. Work in our laboratory described in this review article has been supported by the Consejo Nacional de Investigaciones Cientìficas (CON-ICET), Agencia Nacional de Promociòn Cientìfica y Tecnològica, and Universidad Nacional del Sur, Argentina.

#### References

- Baran, D.T., Quail, J.M., Ray, R., Leszyk, J., Honeyman, 2000. Annexin II is the membrane receptor that mediates the rapid actions of 1alpha, 25-dihydroxyvitamin D(3). J. Cell. Biochem. 78, 34–46.
- Bauman, V.K., Valinietse, M.Y., Babarykin, D.A., 1984. Vitamin D3 and 1,25dihydroxy-vitamin D3 stimulate the skeletal muscle-calcium mobilization in rachitic chicks. Arch. Biochem. Biophys. 231, 211–216.
- Birnbaumer, L., Zhu, X., Jiang, M., Boulay, G., Peyton, M., Vannier, B., Brown, D., Platano, D., Sadeghi, H., Stefani, E., Birnbaumer, M., 1996. On the molecular basis and regulation of cellular capacitative calcium entry: roles for Trp proteins. Proc. Natl Acad. Sci. USA 93, 15195–15202.
- Boland, R., Norman, A.W., Ritz, E., Hasselbach, W., 1985. Presence of a 1,25dihydroxy-vitamin D3 receptor in chicken skeletal muscle myoblasts. Biochem. Biophys. Res. Commun. 128, 305–311.
- Boland, R., 1986. Role of vitamin D in skeletal muscle function. Endocr. Rev. 7, 434–448.
- Boland, A.R., Flawia, M., Coso, O., Boland, R., 1991. A guanine-nucleotide protein mediates 1,25-dihydroxy-vitamin D3-dependent rapid stimulation of Ca<sup>2+</sup> uptake in skeletal muscle. Biochim. Biophys. Acta 1094, 238–242.
- Boland, R., de Boland, A.R., Buitrago, C., Morelli, S., Santillán, G., Vazquez, G., Capiati, D., Baldi, C., 2002. Non-genomic stimulation of tyrosine phosphorylation cascades by 10,25(OH)2D3 by VDR-dependent and -independent mechanisms in muscle cells. Steroids 67, 477–482.
- Boland, R., 2005. Vitamin D and Muscle. In: Feldman, D., Pike, J.W., Glorieux, F.H. (Eds.), Vitamin D. Elsevier Academic Press, San Diego, pp. 883–897.
  Boland, R., Buitrago, C., de Boland, A.R., 2005. Modulation of tyrosine
- Boland, R., Buitrago, C., de Boland, A.R., 2005. Modulation of tyrosine phosphorylation signaling pathways by 1alpha,25(OH)2-vitamin D3. Trends Endocrinol. Metab. 16, 280–287.
- Boyan, B.D., Wang, L., Wong, K.L., Jo, H., Schwartz, Z., 2006. Plasma membrane requirements for 1alpha,25(OH)2D3 dependent PKC signaling in chondrocytes and osteoblasts. Steroids 71, 286–290.
- Buitrago, C., Vazquez, G., de Boland, A.R., Boland, R., 2000. Activation of Src kinase in skeletal muscle cells by 1,25(OH)2-vitamin D3 correlates with tyrosine phosphorylation of the vitamin D receptor (VDR) and VDR-Src interaction. J. Cell. Biochem. 79, 274–281.
- Buitrago, C., Vazquez, G., de Boland, A.R., Boland, R., 2001a. The vitamin D receptor mediates rapid changes in muscle protein tyrosine phosphorylation induced by 1,25(OH)2D3. Biochem. Biophys. Res. Commun. 289, 1150–1156.
- Buitrago, C., Boland, R., de Boland, A.R., 2001b. The tyrosine kinase c-Src is required for 1,25(OH)2-vitamin D3 signaling to the nucleus in muscle cells. Biochim. Biophys. Acta 1541, 179–187.
   Buitrago, C., González Pardo, V., de Boland, A.R., 2002. Nongenomic action of 1alpha,
- Buitrago, C., González Pardo, V., de Boland, A.R., 2002. Nongenomic action of 1alpha, 25(OH)2-vitamin D3 Activation of muscle cell PLC gamma through the tyrosine kinase c-Src and PtdIns 3-kinase. Eur. J. Biochem. 269, 2506–2515.
- Buitrago, C., Gonzalez Pardo, V., de Boland, A.R., Boland, R., 2003. Activation of Raf-1 through Ras and protein kinase Cα mediates 1α,25(OH)2-vitamin D3 regulation of the mitogen-activated protein kinase pathway in muscle cells. J. Biol. Chem. 278, 2199–2205.

- Buitrago, C.G., Ronda, A.C., de Boland, A.R., Boland, R., 2006. MAP kinases p38 and JNK are activated by the steroid hormone 1alpha, 25(OH)2-vitamin D3 in the C2C12 muscle cell line. J. Cell. Biochem. 97, 698–708.
  Buitrago, C., Boland, R., 2010. Caveolae and caveolin-1 are implicated in
- Buitrago, C., Boland, R., 2010. Caveolae and caveolin-1 are implicated in 1%,25(OH)2-vitamin D3-dependent modulation of Src, MAPK cascades and VDR localization in skeletal muscle cells. J. Steroid Biochem. Mol. Biol. 121, 169– 175.
- Capiati, D.A., Vazquez, G., Tellez-Inon, M.T., Boland, R., 2000. Role of PKC in 1,25(OH)2-vitamin D3 regulation of intracellular calcium levels during development of skeletal muscle cells in culture. J. Cell. Biochem. 77, 200–212.
- Capiati, D.A., Vazquez, G., Boland, R., 2001. Protein kinase C modulates the Ca<sup>2+</sup> influx phase of the Ca<sup>2+</sup> response to 1,25-dihydroxy-vitamin D3 in skeletal muscle cells. Horm. Metab. Res. 33, 201–206.
- Capiati, D., Benassati, S., Boland, R., 2002. 1,25(OH)2-vitamin D3 induces translocation of the vitamin D receptor (VDR) to the plasma membrane in skeletal muscle cells. J. Cell. Biochem. 86, 128–135.
- Chen, J., Olivares-Navarrate, R., Wang, Y., Herman, T.R., Boyan, B.D., Schwartz, A., 2010. Protein-disulfide isomerase-associated 3 (Pdia) mediates the membrane response to 1,25-dihydroxyvitamin D3 in osteoblasts. J. Biol. Chem. 285, 37041– 37050.
- Costa, E.M., Blau, H.M., Feldman, D., 1986. 1,25-dihydroxy-vitamin D3 receptors and hormonal responses in human skeletal muscle cells. Endocrinology 119, 2214– 2220.
- de Boland, A.R., Boland, R., 1987. Rapid changes in skeletal muscle calcium uptake induced in vitro by 1,25-dihydroxyvitamin D3 are suppressed by calcium channel blockers. Endocrinology 120, 1858–1864.
- de Boland, A.R., Morelli, S., Boland, R., 1994. 1,25(OH)2-vitamin D3 signal transduction in chick myoblasts involves phosphatidylcholine hydrolysis. J. Biol. Chem. 269, 8675–8679.
- de Boland, A.R., Boland, R., 1994. Non-genomic signal transduction pathway of vitamin D in muscle. Cell. Signal. 6, 717–724.
- de Boland, A.R., Morelli, S., Boland, R., 1995. 1,25(OH)2-vitamin D3 stimulates phospholipase A2 activity via a guanine nucleotide-binding protein in chick myoblasts. Biochim. Biophys. Acta 1257, 274–278.
- Fernandez, L.M., Massheimer, V., de Boland, A.R., 1990. Cyclic AMP-dependent membrane protein phosphorylation and calmodulin binding are involved in the rapid stimulation of muscle calcium uptake by 1,25-dihydroxyvitamin D3. Calcif. Tissue Int. 47, 314–319.
- Huber, A., Sander, P., Bahner, M., Paulsen, R., 1998. The TRP Ca<sup>2+</sup> channel assembled in a signaling complex by the PDZ domain protein INAD is phosphorylated through the interaction with protein kinase C (εPKC). FEBS Lett. 425, 317–322.
- Huhtakangas, J.A., Olivera, C.J., Bishop, J.E., Zanello, L.P., Norman, A.W., 2004. The vitamin D receptor is present in caveolae-enriched plasma membranes and binds 1alpha,25(OH)2-vitamin D3 in vivo and in vitro. Mol. Endocrinol. 18, 2660–2671.
- Khanal, R.C., Nemere, I., 2007. The Erp57/GRp58/1,25D3-MARRS receptor: multiple functional roles in diverse cell systems. Curr. Med. Chem. 14, 1987–11093.
- Kim, Y.S., MacDonald, P.N., Dedhar, S., Hruska, K.A., 1996. Association of 10,25dihydroxyvitamin D3-occupied vitamin D receptors with cellular membrane acceptance sites. Endocrinology 137, 3649–3658.
- Massheimer, V., de Boland, A.R., 1992. Modulation of 1,25-dihydroxyvitamin D3dependent Ca<sup>2+</sup> uptake in skeletal muscle by protein kinase C. Biochem. J. 281, 349–352.
- Mizwicki, M.T., Bishop, J.E., Norman, A.W., 2005. Applications of the vitamin D sterol-vitamin D receptor (VDR) conformational ensemble model. Steroids 70, 464–471.
- Mizwicki, M.T., Bishop, J.E., Olivera, C.J., Huhtakangas, J., Norman, A.W., 2004a. Evidence that annexin II is not a putative membrane receptor for 1alpha, 25(OH)2-vitamin D3. J. Cell. Biochem. 91, 852–863.
- Mizwicki, M.T., Keidel, D., Bula, C.M., Bishop, J.E., Zanello, L.P., Wurtz, J.M., Moras, D., Norman, A.W., 2004b. Identification of an alternative ligand-binding pocket in the nuclear vitamin D receptor and its functional importance in 1alpha, 25(OH)2-vitamin D3 signaling. Proc. Natl Acad. Sci. USA 101, 12876–12881.
- Morelli, S., de Boland, A.R., Boland, R., 1993. Generation of inositol phosphates, diacylglycerol and calcium fluxes in myoblasts treated with 1,25dihydroyvitamin D3. Biochem. J. 289, 675–679.
- Morelli, S., Boland, R., de Boland, A.R., 1996. 1,25(OH)2-vitamin D3 stimulation of phospholipases C and D in muscle cells involves extracellular calcium and a pertussis-sensitive G protein. Mol. Cell. Endocrinol. 122, 207–211.
- Morelli, S., Buitrago, C., Vazquez, G., de Boland, A.R., Boland, K., 2000. Involvement of tyrosine kinase activity in 1,25(OH)2-vitamin D3 signal transduction in skeletal muscle cells. J. Biol. Chem. 275, 36021–36028.
- Morelli, S., Buitrago, C., Boland, R., de Boland, A.R., 2001. The stimulation of MAP kinase by 1,25(OH)2-vitamin D3 in skeletal muscle cells is mediated by protein kinase C and calcium. Mol. Cell. Endocrinol. 173, 41–52.
- Neary, J.I., 1997. MAPK cascades in cell growth and death. News Physiol. Sci. 12, 286–293.
- Nemere, I., Dormanen, N.C., Hammond, M., Okamura, W.H., Norman, A.W., 1994. Identification of a specific binding protein for 1α,25-dihydroxy-vitamin D3 in basal-lateral membranes of chick intestinal epithelium and relationship to transcaltachia. J. Biol. Chem. 269, 23750–23757.
- Nemere, I., Schwartz, S., Pedrozo, H., Sylvia, V.D., Dean, D.D., Boyan, B.D., 1998. Identification of a membrane receptor for 1,25-dihydroxyvitamin D3 which mediates rapid activation of protein kinase C. J. Bone Miner. Res. 13, 1353– 1359.

16

#### R.L. Boland/Molecular and Cellular Endocrinology 347 (2011) 11-16

- Norman, A.W., Olivera, C.J., Barreto Silva, F.R., Bishop, J., 2002. A specific binding protein/receptor for 1alpha, 25-dihydroxyvitamin D3 is present in an intestinal caveolae membrane fraction. Biochem. Biophys. Res. Commun. 298, 414–419. Richard, C.L., Farach-Carson, M.C., Rohe, B., Nemere, I., Meckling, K.A., 2010.
- Richard, C.L., Farach-Carson, M.C., Rohe, B., Nemere, I., Meckling, K.A., 2010. Involvement of 1,25D3-MARRS (membrane associated, rapid response steroidbinding), a novel vitamin D receptor, in growth inhibition of breast cancer cells. Exp. Cell Res. 316, 695–703.Santillán, G., Baldi, C., Katz, S., Vazquez, G., Boland, R., 2004a. Evidence that TRPC3 is
- Santillán, G., Baldi, C., Katz, S., Vazquez, G., Boland, R., 2004a. Evidence that TRPC3 is a molecular component of the 1,25(OH)2D3-activated calcium entry (CCE) in muscle and osteoblast cells. J. Steroid Biochem. Mol. Biol. 89–90, 291–295. Santillán, G., Katz, S., Buitrago, C., Boland, R., 2004b. TRPC3-like protein mediates
- Santillán, G., Katz, S., Buitrago, C., Boland, R., 2004b. TRPC3-like protein mediates 1,25(OH)2D3-induced SOC influx in muscle cells. Int. J. Biochem. Cell Biol. 36, 1910–1918.
- Santillán, G., Katz, S., Buitrago, C., Boland, R., 2004c. 1alpha, 25(OH)2D3 induces capacitative calcium entry involving a TRPC3 protein in skeletal muscle and osteoblastic cells. Biol. Res. 37, 647–651.
- Simpson, R.U., Thomas, G.A., Arnold, A.J., 1985. Identification of 1,25-dihydroxyvitamin D3 receptors and activities in muscle. J. Biol. Chem. 260, 8882–8891.Vazquez, G., de Boland, A.R., 1993. Stimulation of dihydropyridine-sensitive Ca<sup>2+</sup>
- Vazquez, G., de Boland, A.R., 1993. Stimulation of dihydropyridine-sensitive Ca<sup>2+</sup> influx in cultured myoblasts by 1,25(OH)2-vitamin D3. Biochem. Mol. Biol. Int. 31, 677–684.
- Vazquez, G., Boland, R., de Boland, A.R., 1995. Modulation by 1,25(OH)2-vitamin D3 of the adenylyl cyclase/cyclic AMP pathway in rat and chick myoblasts. Biochim. Biophys. Acta 1269, 91–97.

- Vazquez, G., de Boland, A.R., 1996. Involvement of protein kinase C in the modulation of 1,25-dihydroxy-vitamin D3-induced  $45Ca^{2+}$  uptake in rat and chick cultured myoblasts. Biochim. Biophys. Acta 1310, 157–162.
- Vazquez, G., de Boland, A.R., Boland, R., 1997a. 1α,25-(OH)2-vitamin D3 stimulates the adenylyl cyclase pathway in muscle cells by a GTP-dependent mechanism which presumably involves phosphorylation of Gαi. Biochem. Biophys. Res. Commun. 234, 125–128.
- Vazquez, G., de Boland, A.R., Boland, R., 1997b. Stimulation of Ca<sup>2+</sup> release activated Ca<sup>2+</sup> channels as a potential mechanism involved in non-genomic 1,25(OH)2vitamin D3-induced Ca<sup>2+</sup> entry in skeletal muscle cells. Biochem. Biophys. Res. Commun. 239, 562–565.
- Vazquez, G., de Boland, A.R., Boland, R., 1998. 1α,25-dihydroxy-vitamin D3-induced store-operated Ca<sup>2+</sup> influx in skeletal muscle cells. Modulation by phospholipase C, protein kinase C, and tyrosine kinases. J. Biol. Chem. 273, 33954–33960.
- Vazquez, G., de Boland, A.R., Boland, R., 2000. Involvement of calmodulin in 1α,25dihydroxyvitamin D3 stimulation of store-operated Ca<sup>2+</sup> influx in skeletal muscle cells. J. Biol. Chem. 275, 16134–16138.
- Wang, Y., DeLuca, H.F., 2011. Is the vitamin D receptor found in muscle? Endocrinology 152, 354–363.
- Zanello, S.B., Collins, E.D., Marinissen, M.J., Norman, A.W., Boland, R., 1997. Vitamin D receptor expression in chicken muscle tissue and cultured myoblasts. Horm. Metab. Res. 29, 231–236.